These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34611900)
1. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Liles DK; Shah NR; Scullin B; Gordeuk VR; Smith WR; Kanter J; Achebe MM; Boccia R; Crary SE; Kraft WK; Archer N; Cataldo V; Hardesty BM; Idowu M; Desai PC; Ikeda A; Puthenveetil G; Hassell KL; Sarnaik S; Kutlar A Br J Haematol; 2021 Nov; 195(4):e150-e153. PubMed ID: 34611900 [No Abstract] [Full Text] [Related]
2. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. Han J; Saraf SL; Gordeuk VR Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885 [TBL] [Abstract][Full Text] [Related]
3. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701 [TBL] [Abstract][Full Text] [Related]
4. A critical evaluation of crizanlizumab for the treatment of sickle cell disease. Karki NR; Saunders K; Kutlar A Expert Rev Hematol; 2022 Jan; 15(1):5-13. PubMed ID: 34942078 [TBL] [Abstract][Full Text] [Related]
5. Crizanlizumab: First Approval. Blair HA Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169 [TBL] [Abstract][Full Text] [Related]
6. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335 [TBL] [Abstract][Full Text] [Related]
7. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report. Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115 [TBL] [Abstract][Full Text] [Related]
8. Haptoglobin genotype predicts severe acute vaso-occlusive pain episodes in children with sickle cell anemia. Willen SM; McNeil JB; Rodeghier M; Kerchberger VE; Shaver CM; Bastarache JA; Steinberg MH; DeBaun MR; Ware LB Am J Hematol; 2020 Apr; 95(4):E92-E95. PubMed ID: 31919880 [No Abstract] [Full Text] [Related]
9. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Kutlar A; Ataga KI; McMahon L; Howard J; Galacteros F; Hagar W; Vichinsky E; Cheung AT; Matsui N; Embury SH Am J Hematol; 2012 May; 87(5):536-9. PubMed ID: 22488107 [TBL] [Abstract][Full Text] [Related]
10. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292 [TBL] [Abstract][Full Text] [Related]
12. Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series. Idowu M; Garcia RL; Sule OB J Investig Med High Impact Case Rep; 2023; 11():23247096231191873. PubMed ID: 37731262 [TBL] [Abstract][Full Text] [Related]
13. Real-world experience of patients with sickle cell disease treated with crizanlizumab. Chan KH; Buddharaju R; Idowu M J Investig Med; 2024 Feb; 72(2):242-247. PubMed ID: 38073007 [TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease. Sy SKB; Tanaka C; Grosch K Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836 [TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia. Chaturvedi S; Bhatnagar P; Bean CJ; Steinberg MH; Milton JN; Casella JF; Barron-Casella E; Arking DE; DeBaun MR Blood; 2017 Aug; 130(5):686-688. PubMed ID: 28584135 [No Abstract] [Full Text] [Related]
16. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel. Kanter J; Ataga KI; Bhasin N; Guarino S; Kutlar A; Lanzkron S; Manwani D; McGann P; Stowell SR; Tubman VN; Yermilov I; Campos C; Broder MS Ann Hematol; 2024 Jun; 103(6):1909-1917. PubMed ID: 38642304 [TBL] [Abstract][Full Text] [Related]